WeightWatchers and Novo Nordisk Expand Partnership to Improve Wegovy Access

 

Krissy Vann | Host, All Things Fitness and Wellness

WeightWatchers, has announced an expanded collaboration with Novo Nordisk aimed at increasing access to Wegovy, the FDA-approved semaglutide injection used for chronic weight management. The announcement includes a temporary price reduction and new pharmacy integration features that aim to streamline access and improve long-term outcomes for individuals managing obesity.

As of July 1, eligible members of the WeightWatchers Clinic can access Wegovy for 299 dollars through the NovoCare Pharmacy program. The offer is available through the end of the month and represents a 200-dollar discount for cash-pay members. It is part of a broader effort to make GLP-1-based medications more affordable for those paying out of pocket.

The collaboration includes direct fulfillment and home delivery supported by CenterWell Pharmacy, which has received national recognition for customer satisfaction. WeightWatchers Clinic members will also have access to integrated account features, real-time inventory visibility, and bundled pricing.

"By deepening our collaboration with Novo Nordisk, we are helping more people access the FDA-approved treatment they deserve, delivered within a holistic clinical model proven to support real, sustainable and improved health outcomes," said Scott Honken, Chief Commercial Officer at WeightWatchers. "In a market increasingly cluttered with hype and shortcuts, WeightWatchers remains the trusted leader, bringing together access to safe, FDA-approved medication and best-in-class lifestyle support, setting the bar for the gold standard of responsible weight management."

The companies also plan to collaborate on real-world research. The goal is to evaluate how Wegovy performs when paired with WeightWatchers' nutrition and behavioral support model, including clinical and economic impact. This focus on long-term adherence and outcomes could shape future standards in obesity care.

"As we work to expand access to life-changing, FDA-approved treatments like Wegovy, it is essential that we partner with organizations that share our values and focus on improving long-term outcomes," said Dave Moore, Executive Vice President, U.S. Operations of Novo Nordisk Inc. "In a space crowded with quick-fix promises, and unapproved and unsafe compounded medications, we are excited to collaborate with WeightWatchers and their science-backed, responsible approach to care. Their focus on behavioral support, real-world outcomes, and FDA-approved treatment aligns with our values. We believe this expanded collaboration will help more people access safe, effective, and sustainable weight management."

Wegovy was first approved by the FDA in 2021 and remains the only semaglutide medication approved specifically for weight loss. It is currently used by approximately 1.5 million people in the United States. In 2024, the FDA expanded its use to include reducing the risk of major cardiovascular events in adults with heart disease and obesity or overweight.

A recent study of more than 3,200 WeightWatchers Clinic members prescribed a GLP-1 found that participants lost an average of 21 percent of their body weight after 12 months. The results support the idea that combining medical therapy with structured lifestyle support can lead to more sustainable outcomes.

For fitness business operators, this partnership signals continued integration between medical weight loss and consumer wellness brands. It raises important considerations around how gyms and wellness programs may align with or compete against structured medical models that offer comprehensive support.

 
 

Check This Out:

 
Previous
Previous

GymNation’s Ice-Cold Innovation Beats the Dubai Heat With “The Coolest Class”

Next
Next

Syntis Bio Secures $33 Million to Advance Oral Weight Loss Therapies